1. Nationwide trends in the incidence and outcome of patients with gastrointestinal stromal tumour in the imatinib era;van der Graaf;Br J Surg,2018
2. Gastrointestinal stromal tumours: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up;Casali;Ann Oncol,2022
3. Common Terminology Criteria for Adverse Events (CTCAE) v5.0 2024 https://ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm.
4. [Successful reintroduction of mesylate imatinib after pneumonitis in two patients with gastrointestinal stromal tumor (GIST)];Izumiyama;Nihon Kokyuki Gakkai Zasshi,2009
5. Corticosteroid-responsive interstitial pneumonitis related to imantinib mesylate with successful rechallenge, and potential causative mechanisms;Grimison;Internal Medicine Journal,2005